3.25MMarket Cap-590P/E (TTM)
4.9000High4.3600Low21.85KVolume4.5100Open4.5000Pre Close98.60KTurnover3.06%Turnover RatioLossP/E (Static)718.03KShares15.696052wk High0.39P/B3.23MFloat Cap2.414052wk Low--Dividend TTM713.92KShs Float3210.0000Historical High--Div YieldTTM12.00%Amplitude2.4000Historical Low4.5120Avg Price1Lot Size
InMed Pharmaceuticals Stock Forum
newsfile· 5 mins ago
Cannabinol modulates distinct endocannabinoid system elements and exerts anti-inflammatory effectsSupports therapeutic potential of cannabinol for inflammatory skin diseases such as psoriasis, atopic dermatitis and pruritusAnti-inflammatory effects of cannabinol show potential for therapeutic and cosmetic application
InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules
InMed Pharmaceuticals (NASDAQ: INM) has announced a 1-for-20 share consolidation to regain compliance with Nasdaq's listing requirements. The consolidation will reduce outstanding shares from 14,361,550 to approximately 718,078 common shares. The post-consolidation shares are expected to begin trading on Nasdaq Capital Market on November 15, 2024. The trading symbol 'INM' will remain unchanged...
No comment yet